Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest

Main Article Content

Kristian Reich
Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, Univ ers ity Medical Center Hamburg Eppendorf, Hamburg, DE

Eric Simpson
Department of Dermatology, Oregon Health & Science University, Portland, OR, USA

Richard Langley
Division of Clinical Dermatology and Cutaneous Science, Dalhousie University, Halifax, Nova Scotia, CA

Richard Warren
Dermatology Centre, Salford Royal NHS Foundation Trust and NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK

Antonio Costanzo
Dermatology Unit Department of Biomedical Sciences, Humanitas University, Milano, IT; Skin Pathology Laboratory, Humanitas Research Hospital IRCCS, Milano, IT

Hidehisa Saeki
Department of Dermatology, Nippon Medical School, Tokyo, JP

Peter Almgren
LEO Pharma A/S, Ballerup, Denmark

Le Gjerum
LEO Pharma A/S, Ballerup, Denmark

Anna Carlsson
LEO Pharma A/S, Ballerup, Denmark

Melinda Gooderham
SKiN Centre for Dermatology, Peterborough, ON, CA; Department of Dermatology, Queen's University, Kingston, ON, CA; Probity Medical Research, Waterloo, ON, CA;

Andreas Pinter
Department of Dermatology, Venereology, and Allergology, Goethe Universität Frankfurt am Main, Frankfurt am Main, DE

Marjolein De Bruin Weller
Department of Dermatology and Allergology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, NL

Andrew Blauvelt
Oregon Medical Research Center, Portland, OR, USA

Keywords

atopic dermatitis, tralokinumab

References

1. Nutten S. Ann Nutr Metab. 2015;66(Suppl1):8-16.

2. Weidinger S, Novak N. Lancet. 2016;387:1109-22.

3. Popovic B, et al. J Mol Biol. 2017;429:208-19.

4. Wollenberg A, et al. Br J Dermatol. 2021;184(3):437-449.

5. Silverberg JI, et al. Br J Dermatol. 2021;184(3):450-463.

6. Blauvelt A, et al. J Am Acad Dermatol. 2022;S0190-9622(22)02345-3.

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.143

Article Details

How to Cite
[1]
Reich, K., Simpson, E., Langley, R., Warren, R., Costanzo, A. , Saeki, H., Almgren, P., Gjerum, L., Carlsson, A., Gooderham, M., Pinter, A., De Bruin Weller, M. and Blauvelt, A. 2023. Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s143. DOI:https://doi.org/10.25251/skin.7.supp.143.
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>